MEI Pharma Announces First Patient Dosed In Clinical Study Evaluating ME-344 Plus Bevacizumab In Patients With Previously Treated Metastatic Colorectal Cancer
Portfolio Pulse from Happy Mohamed
MEI Pharma, Inc. (NASDAQ:MEIP) has announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab in patients with previously treated metastatic colorectal cancer. The company anticipates announcing safety and efficacy data from the first cohort of 20 ME-344 patients in the first half of 2024.
August 16, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MEI Pharma has initiated a Phase 1b study for ME-344, which could potentially lead to a new treatment for metastatic colorectal cancer. This could have a positive impact on the company's stock.
The initiation of a new clinical trial is generally seen as a positive development for a pharmaceutical company, as it indicates progress in the company's pipeline. If the trial is successful, it could lead to a new treatment option for metastatic colorectal cancer, which could significantly boost MEI Pharma's revenues and profitability.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100